Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme Tissue Repair

This article was originally published in The Gray Sheet

Executive Summary

Senior VP Russell Herndon is promoted to president, effective Jan. 1, 2000. Herndon, who joined the company in 1989, replaces Tim Surgenor, who is leaving "to pursue other interests"

You may also be interested in...

Genzyme Surgical Is Out Of General's Shadow Following January Run-up

Wall Street began to take note in January of Genzyme Surgical Products' leading position in the minimally invasive cardiac surgery market, as the stock price of the Genzyme General spin-off jumped 74.2%. The issue closed the month at 10-1/8, up 5-3/16.

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts